TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide

New messaging reflects TFS’s commitment to patient-centered clinical research and global partnerships

LUND, Sweden, Sept. 19, 2024 /PRNewswire/ — TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), proudly announces the launch of its new mission statement and tagline: Empowering Partners. Enriching Lives. This strategic shift underscores TFS’s commitment to advancing clinical research, improving patient outcomes, and fostering sustainable partnerships.

The refreshed mission—to empower partners to advance treatments that promote global health and well-being—marks a deepened focus on transforming patient care through innovative drug development. With patient-centered care at its core, TFS reinforces its role as a CRO that not only supports the pharmaceutical industry but drives meaningful impact on global health.

TFS specializes in key therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology, making it a standout partner among global mid-sized CROs. These focus areas enable TFS to address some of the most pressing health challenges while delivering tailored clinical research solutions for its partners.

TFS’s new mission was shaped by a diverse focus group, who helped redefine the company’s identity, emphasizing sustainability, diversity, and the global impact of clinical trials. This inclusive approach ensures that TFS is aligned with the evolving needs of its partners while maintaining a patient-centered and people-first philosophy.

“Our new mission and tagline are more than a rebranding exercise; they define our purpose,” said Patrik Darsund, Chief People Officer at TFS. “We are committed to making a lasting difference by empowering our partners and enriching the lives of patients through every trial, every innovation, and every collaboration.”

For over two decades, TFS has built a reputation for delivering clinical research excellence, and this new mission reinforces its ongoing evolution. By combining the global reach of a large CRO with the flexibility and responsiveness of a mid-sized organization, TFS continues to support its clients and partners in navigating the complexities of the healthcare landscape.

“TFS is at a pivotal moment in its evolution,” said Dr. Bassem Saleh, CEO of TFS HealthScience. “We are committed to staying true to our core values while evolving to meet tomorrow’s challenges. By empowering our clients and keeping patients at the center of what we do, we continue to serve as a trusted partner.”

CONTACT:

Emma Primon
Executive Director, Marketing & Communications
emma.primon@tfscro.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/tfs/r/tfs-healthscience-unveils-mission-to-empower-partners-and-enrich-lives-worldwide,c4039665

View original content:https://www.prnewswire.com/news-releases/tfs-healthscience-unveils-mission-to-empower-partners-and-enrich-lives-worldwide-302252995.html

SOURCE TFS

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

3 seconds ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

14 seconds ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago